Literature DB >> 21273081

A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.

Sungwook Choi1, Jeffery W Kelly.   

Abstract

Herein we demonstrate that competition between candidate kinetic stabilizer binding to transthyretin (TTR) and stilbene binding to and reaction with the same thyroxine sites within TTR can be utilized to discover potent and highly selective non-covalent TTR amyloidogenesis inhibitors. We report two stilbenes, S1 and S2, for use in distinct competition assays. Each bind selectively to TTR and then chemoselectively react to form an amide bond with the Lys-15 residue of TTR, creating a fluorescent conjugate. We used 28 TTR kinetic stabilizers exhibiting a known spectrum of plasma TTR binding selectivities and TTR amyloid fibril inhibition efficacies to validate the 'TTR fluorescence conjugate competition assay'. The kinetic stabilizers competed with S1 for binding to recombinant TTR in buffer and with S2 for binding to endogenous levels of TTR in human blood serum. In both assay scenarios, we demonstrate that the lower the TTR-stilbene conjugate fluorescence after a 3 h competition, the greater the binding selectivity and potency of the candidate TTR kinetic stabilizer. These assays, particularly the assay utilizing S2 in human serum, replace two assays previously utilized to gather the same information. While not the focus of this manuscript, it is clear that the 'TTR fluorescence conjugate competition assay' could be adapted for high throughput screening applications.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21273081      PMCID: PMC3039427          DOI: 10.1016/j.bmc.2010.12.050

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  79 in total

1.  A stilbene that binds selectively to transthyretin in cells and remains dark until it undergoes a chemoselective reaction to create a bright blue fluorescent conjugate.

Authors:  Sungwook Choi; Derrick Sek Tong Ong; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2010-10-21       Impact factor: 15.419

2.  The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis.

Authors:  X Jiang; J N Buxbaum; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

3.  A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.

Authors:  Sungwook Choi; Natàlia Reixach; Stephen Connelly; Steven M Johnson; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2010-02-03       Impact factor: 15.419

4.  Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A.

Authors:  C C Blake; M J Geisow; S J Oatley; B Rérat; C Rérat
Journal:  J Mol Biol       Date:  1978-05-25       Impact factor: 5.469

5.  Cellular origin of prealbumin in the rat.

Authors:  P Felding; G Fex
Journal:  Biochim Biophys Acta       Date:  1982-06-16

6.  Trans-suppression of misfolding in an amyloid disease.

Authors:  P Hammarström; F Schneider; J W Kelly
Journal:  Science       Date:  2001-09-28       Impact factor: 47.728

7.  Kinetic stabilization of an oligomeric protein by a single ligand binding event.

Authors:  R Luke Wiseman; Steven M Johnson; Matthew S Kelker; Ted Foss; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2005-04-20       Impact factor: 15.419

8.  Reduced IGF-1 signaling delays age-associated proteotoxicity in mice.

Authors:  Ehud Cohen; Johan F Paulsson; Pablo Blinder; Tal Burstyn-Cohen; Deguo Du; Gabriela Estepa; Anthony Adame; Hang M Pham; Martin Holzenberger; Jeffery W Kelly; Eliezer Masliah; Andrew Dillin
Journal:  Cell       Date:  2009-12-11       Impact factor: 41.582

9.  Mechanism of molecular recognition. Structural aspects of 3,3'-diiodo-L-thyronine binding to human serum transthyretin.

Authors:  A Wojtczak; J Luft; V Cody
Journal:  J Biol Chem       Date:  1992-01-05       Impact factor: 5.157

10.  The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.

Authors:  Z Lai; W Colón; J W Kelly
Journal:  Biochemistry       Date:  1996-05-21       Impact factor: 3.162

View more
  14 in total

1.  Aromatic sulfonyl fluorides covalently kinetically stabilize transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate.

Authors:  Neil P Grimster; Stephen Connelly; Aleksandra Baranczak; Jiajia Dong; Larissa B Krasnova; K Barry Sharpless; Evan T Powers; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2013-02-14       Impact factor: 15.419

2.  Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.

Authors:  Mark Miller; Arindom Pal; Wabel Albusairi; Hyun Joo; Beverly Pappas; Md Tariqul Haque Tuhin; Dengpan Liang; Raghavendra Jampala; Fang Liu; Jared Khan; Marjon Faaij; Miki Park; William Chan; Isabella Graef; Robert Zamboni; Neil Kumar; Jonathan Fox; Uma Sinha; Mamoun Alhamadsheh
Journal:  J Med Chem       Date:  2018-08-22       Impact factor: 7.446

Review 3.  Current and future treatment of amyloid diseases.

Authors:  M Ankarcrona; B Winblad; C Monteiro; C Fearns; E T Powers; J Johansson; G T Westermark; J Presto; B-G Ericzon; J W Kelly
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

Review 4.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.

Authors:  Steven M Johnson; Stephen Connelly; Colleen Fearns; Evan T Powers; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2012-01-05       Impact factor: 5.469

Review 5.  A current pharmacologic agent versus the promise of next generation therapeutics to ameliorate protein misfolding and/or aggregation diseases.

Authors:  Aleksandra Baranczak; Jeffery W Kelly
Journal:  Curr Opin Chem Biol       Date:  2016-02-06       Impact factor: 8.822

6.  Peripherally restricted transthyretin-based delivery system for probes and therapeutics avoiding opioid-related side effects.

Authors:  Md Tariqul Haque Tuhin; Dengpan Liang; Fang Liu; Hala Aldawod; Toufiq Ul Amin; Joshua S Ho; Rasha Emara; Arjun D Patel; Melanie A Felmlee; Miki S Park; James A Uchizono; Mamoun M Alhamadsheh
Journal:  Nat Commun       Date:  2022-06-23       Impact factor: 17.694

7.  AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.

Authors:  Sravan C Penchala; Stephen Connelly; Yu Wang; Miki S Park; Lei Zhao; Aleksandra Baranczak; Irit Rappley; Hannes Vogel; Michaela Liedtke; Ronald M Witteles; Evan T Powers; Natàlia Reixach; William K Chan; Ian A Wilson; Jeffery W Kelly; Isabella A Graef; Mamoun M Alhamadsheh
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

8.  Fluorogenic small molecules requiring reaction with a specific protein to create a fluorescent conjugate for biological imaging--what we know and what we need to learn.

Authors:  Aleksandra Baranczak; Stephen Connelly; Yu Liu; Sungwook Choi; Neil P Grimster; Evan T Powers; Ian A Wilson; Jeffery W Kelly
Journal:  Biopolymers       Date:  2014-05       Impact factor: 2.505

9.  Bifunctional coumarin derivatives that inhibit transthyretin amyloidogenesis and serve as fluorescent transthyretin folding sensors.

Authors:  Nojoon Myung; Stephen Connelly; Boyoung Kim; Sung Jean Park; Ian A Wilson; Jeffery W Kelly; Sungwook Choi
Journal:  Chem Commun (Camb)       Date:  2013-08-29       Impact factor: 6.222

10.  A biomimetic approach for enhancing the in vivo half-life of peptides.

Authors:  Sravan C Penchala; Mark R Miller; Arindom Pal; Jin Dong; Nikhil R Madadi; Jinghang Xie; Hyun Joo; Jerry Tsai; Patrick Batoon; Vyacheslav Samoshin; Andreas Franz; Trever Cox; Jesse Miles; William K Chan; Miki S Park; Mamoun M Alhamadsheh
Journal:  Nat Chem Biol       Date:  2015-09-07       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.